Pharmacodynamics PD modelling

Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models... 

Pharmacodynamic (PD) models are used to describe the relationship between drug concentration and drug effect. An overview of various PD models can be found in the literature [21]. The essential elements will be treated in the following sections. 

A pharmacodynamic (PD) model describing the relationship between the observed concentration/exposure measure (e.g. the area under the plasma concentration-time profile AUC) and the observed drug effects on biomarkers, efficacy or safety measurements (or endpoints). Time dependent changes (e.g. development of tolerance) and influence of intrinsic and extrinsic factors should also be reflected in the model. 

Exposures of newborns to PAHs depend on pharmacokinetic processes operating in the mother, and transfer through breast milk. Since it is difficult to characterize these pathways in humans, physiologically based pharmacokinetic (PBPK) and pharmacodynamic (PD) models need to be developed using appropriate animal models, and incorporating key parameters such as dose, exposure duration, and developmental stage (Dorman et al, 2001). Thus, development of PBPK and PBPD models for PAHs is an immediate need that will help in not only characterizing the dose-response relationship, but also extrapolation of results from animal studies to humans. 

---